Oxfordshire Clinical Commissioning Group
Formulary
 
back
11 Eye
11-08-02 Subfoveal choroidal neovascularisation

Aflibercept Eylea®
Formulary

For use by Consultant Ophthalmology in patients with;

  • Wet-age related macular degeneration as per NICE TA294. APCO September 2013.
  • Diabetic macular oedema as per NICE TA346. APCO September 2015.
  • Branch retinal vein occlusion as per NICE TA409. APCO November 2016. Also see Clinical Commissioning Policy 249B
  • Choroidal neovascularisation as per NICE TA486. APCO January 2018.

For sequential use please refer to Clinical Commissioning Policy 267S

Link  NICE TA294: Aflibercept solution for injection for treating wet age‑related macular degeneration
Link  NICE TA346: Aflibercept for treating diabetic macular oedema
Link  NICE TA409: Aflibercept for treating visual impairment caused by macular oedema after branch retinal vein occlusion
Link  NICE TA486: Aflibercept for treating choroidal neovascularisation
 

Red View adult BNF  View SPC online  View childrens BNF  HCD
Ranibizumab Lucentis®
Formulary

For use by Consultant Ophthalmology in patients with;

  • Age related macular degeneration as per NICE TA155. APCO September 2008.
  • Choroidal neovascularisation associated with pathological myopia NICE TA298. APCO January 2014.
  • Diabetic Macular Oedema as per NICE TA274. APCO March 2013.
  • Visual impairment caused by macular oedema secondary to retinal vein occlusion as per NICE TA283. APCO January 2014. Also see Clinical Commissioning Policy 249B.

For sequential use please refer to Clinical Commissioning Policy 267S


Red View adult BNF  View SPC online  View childrens BNF  HCD
Verteporfin Visudyne®
Formulary

For chronic Central Serous Chorioretinopathy(CSR) and Idiopathic Polypoidal Choroidal Vasculopathy (IPCV).

Link  NICE TA68: Photodynamic therapy for age related macular degeneration
 

Red View adult BNF  View SPC online  View childrens BNF  HCD
Bevacizumab
Formulary

For neo-vascularisation in non wet-AMD conditions and glaucoma prior to laser treatment.


Red View adult BNF  View SPC online  View childrens BNF
Pegaptanib Sodium Macugen®
Non Formulary

Not recommended for the treatment of wet age-related macular degeneration as per NICE TA155 (APCO September 2008).

Pfizer withdrew their licensing application for diabetic macular oedema. Therefore NICE appraisal was been suspended (APCO January 2012).

Link  NICE TA155: Ranibizumab and pegaptanib for the treatment of age-related macular degeneration
 

Black View adult BNF  View SPC online  View childrens BNF  HCD